Group 1 - The core viewpoint of the news is the performance and management changes of Guotou Ruijin Fund's healthcare mixed fund, which has seen a decrease in net assets and changes in fund management personnel [1][2][3] Group 2 - As of June 30, 2025, the net assets of Guotou Ruijin Healthcare Mixed C Fund (011082) were 0.15 billion RMB, a decrease of 9.00% compared to the previous period [1] - The fund manager, Liu Zexu, has a background as an industry analyst at CITIC Securities and Shanghai Jinglin Asset Management before joining Guotou Ruijin Fund Management in June 2023 [1] - Recent changes in fund share scale show that the total share at the end of the period was 0.02 billion, with a net asset change rate of -24.80% [2] - The fund's performance over the last three months yielded a return of 15.46%, while the one-year return was 30.33%, and since inception, the return has been -26.81% [2] - The top ten stock holdings of the fund include companies like Heng Rui Medicine and Ke Lun Pharmaceutical, with a total holding percentage of 38.69% [2] - Guotou Ruijin Fund Management Company was established in June 2002, located in Shanghai, with a registered capital of 100 million RMB [2]

来源：金融界 公开信息显示，现任基金经理刘泽序先生:中国,硕士研究生,2016年3月至2022年3月期间任中信证券股份 有限公司研究部行业分析师,2022年3月至2023年6月期间任上海景林资产管理有限公司投资研究部分析 师。2023年6月加入国投瑞银基金管理有限公司基金投资部。2023年9月12日起担任国投瑞银创新医疗灵 活配置混合型证券投资基金基金经理。2024年5月1日担任国投瑞银医疗保健行业灵活配置混合型证券投 资基金基金经理。 截止2025年3月31日，国投瑞银医疗保健混合C前十持仓占比合计39.42%，分别为：恒瑞医药 （6.09%）、泽璟制药-U（5.28%）、科伦药业（5.22%）、药明康德（3.98%）、昆药集团（3.75%）、 泰格医药（3.67%）、东阿阿胶（3.45%）、奥赛康（2.86%）、凯莱英（2.58%）、新诺威（2.54%）。 6月19日，国投瑞银医疗保健混合C（011082）下跌1.23%，最新净值0.87元，连续5个交易日下跌，区间 累计跌幅7.99%。 据了解，国投瑞银医疗保健混合C成立于2020年12月，基金规模0.16亿元，成立来累计收益率-35.71%。 从持有人 ...